Latest & greatest articles for oxybutynin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on oxybutynin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on oxybutynin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for oxybutynin

1. Pelvic floor muscle training alone or in combination with oxybutynin in treatment of nonmonosymptomatic enuresis. A randomized controlled trial with 2-year follow up. (PubMed)

Pelvic floor muscle training alone or in combination with oxybutynin in treatment of nonmonosymptomatic enuresis. A randomized controlled trial with 2-year follow up. To compare the results of the standard urotherapy alone and associated with pelvic floor muscle training alone, and in combination with oxybutynin in treatment of nonmonosymptomatic nocturnal enuresis.A total of 38 children aged 5 to 10 years were randomized into three groups: Group I (n=12) that was submitted to standard (...) urotherapy; Group II (n=15), standard urotherapy associated with pelvic floor muscle training; and Group III (n=11), standard urotherapy associated with pelvic floor muscle training and oxybutynin; the treatment lasted 12 weeks. The assessment tools used were playful bladder diary, and a 48-hour bladder diary, before and after treatment. After 2 years, patients were assessed by telephone using a standardized questionnaire.The data of children from the three groups were homogeneous at baseline. After 12

2019 Einstein (Sao Paulo, Brazil) Controlled trial quality: uncertain

2. The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind Crossover Trial

The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind Crossover Trial Rationale: There is currently no effective pharmacological treatment for obstructive sleep apnea (OSA). Recent investigations indicate that drugs with noradrenergic and antimuscarinic effects improve genioglossus muscle activity and upper airway patency during sleep. Objectives: We aimed to determine the effects of the combination (...) of a norepinephrine reuptake inhibitor (atomoxetine) and an antimuscarinic (oxybutynin) on OSA severity (apnea-hypopnea index [AHI]; primary outcome) and genioglossus responsiveness (secondary outcome) in people with OSA. Methods: A total of 20 people completed a randomized, placebo-controlled, double-blind, crossover trial comparing 1 night of 80 mg atomoxetine plus 5 mg oxybutynin (ato-oxy) to placebo administered before sleep. The AHI and genioglossus muscle responsiveness to negative esophageal pressure

2019 EvidenceUpdates

3. Oxybutynin

Oxybutynin Top results for oxybutynin - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for oxybutynin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

4. Hyperhidrosis: oxybutynin

Hyperhidrosis: oxybutynin Hyperhidrosis: o Hyperhidrosis: oxybutynin xybutynin Evidence summary Published: 21 March 2017 nice.org.uk/guidance/es10 pathways K Ke ey points y points The content of this evidence summary was up-to-date in March 2017. See the summary of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. Regulatory status: Regulatory status: off-label use of a licensed medicine. Oxybutynin is an antimuscarinic (...) medicine that can be used to treat hyperhidrosis (excessive sweating); use for this indication is off-label. Ov Overview erview This evidence summary includes 4 studies (3 randomised controlled trials [RCTs] and 1 quasi- randomised controlled trial) that investigated oxybutynin 2.5 mg to10 mg for treating hyperhidrosis in adults. All the studies compared oxybutynin with placebo and were in non-UK settings. Three studies found that more people treated with oxybutynin reported an improvement in symptoms

2017 National Institute for Health and Clinical Excellence - Advice

5. Desmopressin versus Oxybutynin for Nocturnal Enuresis in Children in Bandar Abbas: A Randomized Clinical Trial. (PubMed)

Desmopressin versus Oxybutynin for Nocturnal Enuresis in Children in Bandar Abbas: A Randomized Clinical Trial. Nocturnal enuresis is among the most common disorders in children. Several pharmacological and non-pharmacological treatments are available for nocturnal enuresis. Studies for reaching the best pharmacological treatment for this disorder are continuing.To compare the effectiveness and safety of Desmopressin and oxybutynin for treatment of nocturnal enuresis in children from Bandar (...) Abbas in 2014.This randomized controlled trial was conducted in 2014 and participants included 66 children with nocturnal enuresis who were more than 5 years old. Patients were randomly assigned into two groups. The first group received 120 microgram Desmopressin daily for 2 months, then 60 microgram daily for 2 months, then 60 microgram every 2 days. The second group received 5 mg oxybutynin twice a day for 6 months. The patients were followed after 1, 3, and 6 months to track treatment response

Full Text available with Trip Pro

2016 Electronic physician Controlled trial quality: uncertain

6. Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom

Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2014 NHS Economic Evaluation Database.

7. SENIOR: Solifenacin (VESICARE) vs Oxybutynin (DITROPAN) vs Placebo Use in Elderly People with Mild Cognitive Impairment (MCI)

SENIOR: Solifenacin (VESICARE) vs Oxybutynin (DITROPAN) vs Placebo Use in Elderly People with Mild Cognitive Impairment (MCI) RXFILES TRIAL SUMMARY K KRAHN BSP STUDENT, L REGIER BSP © WWW.RXFILES.CA MAY 2013 Page 1 of 2 Were the study doses comparative? Oxybutynin 2.5mg BID may have been a more suitable starting dose for these elderly patients. SENIOR: Solifenacin (VESICARE) vs Oxybutynin (DITROPAN) vs Placebo Use in Elderly People with Mild Cognitive Impairment (MCI) 1 BOTTOM LINE At first (...) glance this trial appears to support the use of solifenacin over oxybutynin because of their differing effects on cognition in elderly people with MCI. However, this is somewhat misleading as there was no difference in the primary end-point studied. There is some potential for differences between the two agents based on secondary endpoints. Possible changes in cognition were reported with oxybutynin vs placebo at various time points in the secondary endpoints, but the clinical significance

2013 RxFiles

8. Oxybutynin Chloride Gel - overactive bladder

Oxybutynin Chloride Gel - overactive bladder Common Drug Review CDEC Meeting – March 21, 2012; CDEC Reconsideration – May 16, 2012 Notice of CDEC Final Recommendation – May 24, 2012 Page 1 of 4 © 2012 CADTH CDEC FINAL RECOMMENDATION OXYBUTYNIN CHLORIDE GEL (Gelnique – Watson Laboratories, Inc.) Indication: Bladder, Overactive Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that oxybutynin chloride gel not be listed. Reasons for the Recommendation: 1. The Committee (...) considered the comparative clinical benefit of oxybutynin chloride gel to be uncertain because of the absence of any randomized controlled trials (RCTs) that directly compare it with other pharmacological treatments for overactive bladder. 2. There are no RCTs comparing the incidence of anticholinergic adverse effects (such as cognitive and neurological) between oxybutynin chloride gel and other oxybutynin products, particularly in the elderly. Background: Oxybutynin chloride gel has a Health Canada

2012 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

9. Anturol (oxybutynin), 3% gel

Anturol (oxybutynin), 3% gel Drug Approval Package: ANTUROL NDA #202513 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - ANTUROL (oxybutynin), 3% gel Company: Antares Pharma, Inc. Application No.: 202513 Approval Date: 12/07/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: June 26, 2012 Updated

2012 FDA - Drug Approval Package

10. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service

The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 NHS Economic Evaluation Database.

11. Oxybutynin, tolterodine, and darifenacin: review of cognitive adverse events

Oxybutynin, tolterodine, and darifenacin: review of cognitive adverse events Oxybutynin, tolterodine, and darifenacin: review of cognitive adverse events Oxybutynin, tolterodine, and darifenacin: review of cognitive adverse events Boudreau R, Cimon K, Cunningham J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Boudreau R, Cimon K (...) , Cunningham J. Oxybutynin, tolterodine, and darifenacin: review of cognitive adverse events . Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2009 Authors' conclusions Most of the studies concluded that cognitive function was not affected by taking oxybutynin, tolterodine, or darifenacin. All of the studies were short-term which may not reflect the typical patient on these medications. Three FDA advisories have been issued which stated that there have been reports of cognitive

2009 Health Technology Assessment (HTA) Database.

12. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence (PubMed)

Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence Determine the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence.Randomized, double-blinded, placebo-controlled trial.Twelve skilled nursing homes.Fifty women aged 65 and older with urge (...) incontinence and cognitive impairment.Four-week treatment with once-daily oral extended-release oxybutynin 5 mg or placebo.Withdrawal rates and delirium or change in cognition from baseline at 1, 3, 7, 14, 21, and 28 days after starting treatment using the Confusion Assessment Method (CAM), Mini-Mental State Examination (MMSE), and Severe Impairment Battery (SIB). The Brief Agitation Rating Scale, adverse events, falls incidence, and serum anticholinergic activity change with treatment were also

2008 EvidenceUpdates Controlled trial quality: predicted high

13. Intravesical oxybutynin for children with poorly compliant neurogenic bladder: a systematic review

Intravesical oxybutynin for children with poorly compliant neurogenic bladder: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

14. Oxybutynin transdermal patch (Kentera)

Oxybutynin transdermal patch (Kentera) Scottish Medicines Consortium oxybutynin 3.9mg/24h transdermal patch (Kentera ® ) No. (190/05) UCB Pharma Ltd 8 July 2005 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following a full submission Oxybutynin transdermal patch (Kentera ® ) is accepted for restricted use (...) within NHS Scotland for the treatment of urge incontinence and/or increased urinary frequency and urgency in patients with unstable bladder, restricted to patients who derive clinical benefit from oral oxybutinin but who experience intolerable anticholinergic side effects. It should be used in conjunction with non-pharmacological measures, including pelvic floor muscle exercises and bladder retraining. Transdermal oxybutynin appears to have similar efficacy to oral antimuscarinics and a lower rate

2005 Scottish Medicines Consortium

15. Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence

Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence Hughes D A, Dubois D Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Four treatments for patients with urge incontinence were examined. The specific treatments were oxybutynin extended-release (Oxy-ER), tolterodine extended-release (Tol-ER), oxybutynin immediate-release (Oxy-IR) and tolterodine immediate-release (Tol-IR). Type

2004 NHS Economic Evaluation Database.

16. Cost effectiveness of controlled-release oxybutynin compared with immediate-release oxybutynin and tolterodine in the treatment of overactive bladder in the UK, France and Austria

Cost effectiveness of controlled-release oxybutynin compared with immediate-release oxybutynin and tolterodine in the treatment of overactive bladder in the UK, France and Austria Cost effectiveness of controlled-release oxybutynin compared with immediate-release oxybutynin and tolterodine in the treatment of overactive bladder in the UK, France and Austria Cost effectiveness of controlled-release oxybutynin compared with immediate-release oxybutynin and tolterodine in the treatment (...) of overactive bladder in the UK, France and Austria Guest J F, Abegunde D, Ruiz F J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of controlled-release (CR) oxybutynin (at a dose titrated up to 10 mg/day) for the treatment

2004 NHS Economic Evaluation Database.

17. Oxybutynin extended release and tolterodine immediate release: a health economic comparison

Oxybutynin extended release and tolterodine immediate release: a health economic comparison Oxybutynin extended release and tolterodine immediate release: a health economic comparison Oxybutynin extended release and tolterodine immediate release: a health economic comparison Getsios D, Caro J J, Ishak K J, El-Hadi W, Payne K, O'Connel M, Albrecht D, Feng W, Dubois D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of oxybutynin extended release (XL) and tolterodine immediate release (IR) for the treatment of overactive bladder. The doses used were 10 mg/day (oxybutynin) and 4 mg/day (tolterodine), respectively. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population

2004 NHS Economic Evaluation Database.

18. Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder

Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder Getsios D, Caro J J, Ishak K J, El Hadi W, Payne K Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two pharmacological treatments for overactive bladder (OAB) were examined. These were the new extended-release (XL) formulation of oxybutynin (10 mg/day) and immediate-release (IR) tolterodine (4 mg/day). Type of intervention

2004 NHS Economic Evaluation Database.

19. Transdermally-delivered oxybutynin (Oxytrol(R)) for overactive bladder

Transdermally-delivered oxybutynin (Oxytrol(R)) for overactive bladder Transdermally-delivered oxybutynin (Oxytrol(R)) for overactive bladder Transdermally-delivered oxybutynin (Oxytrol(R)) for overactive bladder Ho C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ho C. Transdermally-delivered oxybutynin (Oxytrol(R)) for overactive (...) bladder. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2001: 4 Authors' objectives To summarise the available evidence on transdermally-delivered oxybutynin (Oxytrol(R)) for overactive bladders. Authors' conclusions - The oxybutynin patch is a transdermal delivery system, which releases the drug oxybutynin through the skin for the management of overactive bladder. - Limited evidence suggests that transdermal delivery of oxybutynin over a short period of time may have

2001 Health Technology Assessment (HTA) Database.

20. Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis

Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2001 DARE.